Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015, 53216-53220 [2014-21280]
Download as PDF
53216
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices
equipment manufacturers, separation
system designers, and end users.
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2014–21286 Filed 9–5–14; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–393]
Established Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2015
Drug Enforcement
Administration (DEA), Department of
Justice (DOJ).
ACTION: Notice.
AGENCY:
This notice establishes the
initial 2015 aggregate production quotas
for controlled substances in schedules I
and II of the Controlled Substances Act
(CSA) and the assessment of annual
needs for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
DATES: Effective date: Effective
September 8, 2014.
FOR FURTHER INFORMATION CONTACT:
Imelda Paredes, Executive Assistant,
Office of Diversion Control, Drug
Enforcement Administration, 8701
Morrissette Drive, Springfield, VA
22152, Telephone: (202) 598–6812.
SUPPLEMENTARY INFORMATION:
rmajette on DSK2TPTVN1PROD with NOTICES
SUMMARY:
Legal Authority
The Drug Enforcement
Administration (DEA) implements and
enforces titles II and III of the
Comprehensive Drug Abuse Prevention
and Control Act of 1970, as amended.
Titles II and III are referred to as the
‘‘Controlled Substances Act’’ and the
‘‘Controlled Substances Import and
Export Act,’’ respectively, and are
collectively referred to as the
‘‘Controlled Substances Act’’ or the
‘‘CSA’’ for the purpose of this action. 21
U.S.C. 801–971. The DEA publishes the
implementing regulations for these
statutes in title 21 of the Code of Federal
Regulations (CFR), parts 1300 to 1321.
The CSA and its implementing
regulations are designed to prevent,
detect, and eliminate the diversion of
controlled substances and listed
chemicals into the illicit market while
providing for the legitimate medical,
scientific, research, and industrial needs
VerDate Mar<15>2010
15:14 Sep 05, 2014
Jkt 232001
of the United States. Controlled
substances have the potential for abuse
and dependence and are controlled to
protect the public health and safety.
Section 306 of the Controlled
Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in schedules I and II
and for ephedrine, pseudoephedrine,
and phenylpropanolamine. This
responsibility has been delegated to the
Administrator of the DEA through 28
CFR 0.100(b). The Administrator, in
turn, has redelegated this function to the
Deputy Administrator, pursuant to 28
CFR pt. 0 subpt. R, App.
Background
The 2015 aggregate production quotas
and assessment of annual needs
represent those quantities of schedule I
and II controlled substances and the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine to be
manufactured in the United States in
2015 to provide for the estimated
medical, scientific, research, and
industrial needs of the United States,
lawful export requirements, and the
establishment and maintenance of
reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine,
and phenylpropanolamine but do not
include imports of controlled
substances for use in industrial
processes.
On July 2, 2014, a notice titled,
‘‘Proposed Aggregate Production Quotas
for Schedule I and II Controlled
Substances and Proposed Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2015’’ was
published in the Federal Register. 79 FR
37772. This notice proposed the 2015
aggregate production quotas for each
basic class of controlled substance listed
in schedules I and II and the 2015
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine. All interested
persons were invited to comment on or
object to the proposed aggregate
production quotas and the proposed
assessment of annual needs on or before
August 1, 2014.
Comments Received
Five comments were received from
DEA-registered manufacturers within
the published comment period, offering
comments on a total of 32 schedule I
and II controlled substances. None of
the respondents commented on the list
I chemicals ephedrine,
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
pseudoephedrine, and
phenylpropanolamine. Commenters
stated that the proposed aggregate
production quotas for 1-(1,3Benzodioxol-5-yl)-2-(methylamino)
butan-1-one (butylone), 1-(1,3Benzodioxol-5-yl)-2-(methylamino)
pentan-1-one (pentylone), 2-(4-Bromo2,5-dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1phenylpentan-1-one (pentedrone), 3Fluoro-N-methylcathinone (3-FMC), 4Fluoro-N-methylcathinone (4-FMC), 4Anilino-N-phenethyl-4-piperidine
(ANPP), 4-Methyl-N-ethylcathinone (4MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP),
alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone
(a-PVP), amphetamine (for sale),
codeine (for sale), dihydrocodeine,
diphenoxylate, fentanyl, hydrocodone
(for sale), hydromorphone, levorphanol,
marihuana, morphine (for conversion),
N-(1-Amino-3,3-dimethyl-1-oxobutan-2yl)-1-pentyl-1H-indazole-3-carboxamide
(ADB-PINACA), N-(1-Amino-3-methyl1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (ABFUBINACA), naphthylpyrovalerone
(naphyrone), oripavine, oxycodone (for
conversion), oxymorphone (for
conversion), oxymorphone (for sale),
Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB-22),
and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22) were insufficient to
provide for the estimated medical,
scientific, research, and industrial needs
of the United States, export
requirements, and the establishment
and maintenance of reserve stocks.
Determination of 2015 Aggregate
Production Quotas and Assessment of
Annual Needs
In determining the 2015 aggregate
production quotas and assessment of
annual needs, the DEA has taken into
consideration the above comments
along with the factors set forth at 21
CFR 1303.11 and 21 CFR 1315.11, in
accordance with 21 U.S.C. 826 (a), and
other relevant factors, including the
consideration of 2014 manufacturing
quotas, current 2014 sales and
inventories, 2015 export requirements,
industrial use, additional applications
for quotas, as well as information on
research and product development
requirements. Based on this
information, the DEA has determined
E:\FR\FM\08SEN1.SGM
08SEN1
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices
that adjustments to the proposed
aggregate production quotas and
assessment of annual needs for
alfentanil, cocaine, codeine-N-oxide,
codeine (for sale), dihydrocodeine,
fentanyl, hydromorphone, levorphanol,
marihuana, oripavine, oxymorphone
(for conversion), and ephedrine (for
sale) are warranted. This notice reflects
those adjustments.
Regarding 1-(1,3-Benzodioxol-5-yl)-2(methylamino)butan-1-one (butylone),
1-(1,3-Benzodioxol-5-yl)-2(methylamino)pentan-1-one (pentylone),
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25BNBOMe), 2-(4-Chloro-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25CNBOMe), 2-(4-Iodo-2,5dimethoxyphenyl)-N-(2methoxybenzyl)ethanamine (25INBOMe), 2-(Methylamino)-1phenylpentan-1-one (pentedrone), 3Fluoro-N-methylcathinone (3-FMC), 4Fluoro-N-methylcathinone (4-FMC), 4Anilino-N-phenethyl-4-piperidine
(ANPP), 4-Methyl-N-ethylcathinone (4MEC), 4-Methyl-apyrrolidinopropiophenone (4-MePPP),
alpha-Pyrrolidinobutiophenone (aPBP), alpha-Pyrrolidinopentiophenone
(a-PVP), amphetamine (for sale),
dihydrocodeine, fentanyl,
hydromorphone, levorphanol,
marihuana, N-(1-Amino-3,3-dimethyl-1oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide (ADB-PINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB-FUBINACA),
naphthylpyrovalerone (naphyrone),
oxycodone (for conversion),
oxymorphone (for sale), Quinolin-8-yl 1(5-fluoropentyl)-1H-indole-3carboxylate (5-Flouro-PB-22), and
Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB-22), the DEA has
determined that the proposed aggregate
production quotas are sufficient to
provide for the 2015 estimated medical,
scientific, research, and industrial needs
of the United States, export
requirements, and the establishment
and maintenance of reserve stocks. This
notice finalizes these aggregate
production quotas at the same amounts
as proposed.
As described in the previously
published notice proposing the 2015
aggregate production quotas and
assessment of annual needs, the DEA
has specifically considered that
inventory allowances granted to
individual manufacturers may not
always result in the availability of
sufficient quantities to maintain an
adequate reserve stock pursuant to 21
U.S.C. 826(a), as intended. See 21 CFR
1303.24. This would be concerning if a
natural disaster or other unforeseen
event resulted in substantial disruption
to the amount of controlled substances
available to provide for legitimate
53217
public need. As such, the DEA has
included in all established schedule II
aggregate production quotas, and certain
schedule I aggregate production quotas,
an additional 25% of the estimated
medical, scientific, and research needs
as part of the amount necessary to
ensure the establishment and
maintenance of reserve stocks. The
resulting established aggregate
production quota will reflect these
included amounts. This action will not
affect the ability of manufacturers to
maintain inventory allowances as
specified by regulation. The DEA
expects that maintaining this reserve in
certain established aggregate production
quotas will mitigate adverse public
effects if an unforeseen event results in
the substantial disruption to the amount
of controlled substances available to
provide for legitimate public need, as
determined by the DEA. The DEA does
not anticipate utilizing the reserve in
the absence of these circumstances.
In accordance with 21 U.S.C. 826, 21
CFR 1303.11, and 21 CFR 1315.11, the
Deputy Administrator hereby
establishes the 2015 aggregate
production quotas for the following
schedule I and II controlled substances
and the 2015 assessment of annual
needs for the list I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Established
2015 quotas (g)
Basic class
rmajette on DSK2TPTVN1PROD with NOTICES
Schedule I
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ...........................................................................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) .............................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ...............................................................................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ...........................................................................................
1-(1-Phenylcyclohexyl)pyrrolidine ................................................................................................................................................
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ....................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ...................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...........................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) .......................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073) ....................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ...................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ...................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine ...................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ..............................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ....................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) ................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ....................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ...................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) ............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ...............................................................................................................
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P) ..............................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ...................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) ................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) ..................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ...............................................................................................................................
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) ................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) ................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) ................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ......................................................................................................................
VerDate Mar<15>2010
15:14 Sep 05, 2014
Jkt 232001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
E:\FR\FM\08SEN1.SGM
08SEN1
15
15
15
15
10
45
45
15
45
45
45
45
2
45
45
45
45
45
45
45
30
30
30
30
30
15
30
15
30
53218
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices
Established
2015 quotas (g)
rmajette on DSK2TPTVN1PROD with NOTICES
Basic class
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) ..........................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone) .................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ..............................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine .............................................................................................................................
2,5-Dimethoxyamphetamine ........................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) ........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) ..................................................................................................
3,4,5-Trimethoxyamphetamine ....................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ....................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .........................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .....................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ..................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) ...................................................................................................................................
3-Fluoro-N-methylcathinone (3-FMC) ..........................................................................................................................................
3-Methylfentanyl ...........................................................................................................................................................................
3-Methylthiofentanyl .....................................................................................................................................................................
4-Bromo-2,5-dimethoxyamphetamine (DOB) ..............................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ..........................................................................................................................
4-Fluoro-N-methylcathinone (4-FMC) ..........................................................................................................................................
4-Methoxyamphetamine ..............................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ..............................................................................................................................
4-Methylaminorex ........................................................................................................................................................................
4-Methyl-N-ethylcathinone (4-MEC) ............................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ................................................................................................................................
4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) .......................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) ...................
5-Methoxy-3,4-methylenedioxyamphetamine ..............................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..........................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine .............................................................................................................................................
Acetyl-alpha-methylfentanyl .........................................................................................................................................................
Acetyldihydrocodeine ...................................................................................................................................................................
Acetylmethadol ............................................................................................................................................................................
Allylprodine ..................................................................................................................................................................................
Alphacetylmethadol ......................................................................................................................................................................
alpha-Ethyltryptamine ..................................................................................................................................................................
Alphameprodine ...........................................................................................................................................................................
Alphamethadol .............................................................................................................................................................................
alpha-Methylfentanyl ....................................................................................................................................................................
alpha-Methylthiofentanyl ..............................................................................................................................................................
alpha-Methyltryptamine (AMT) ....................................................................................................................................................
alpha-Pyrrolidinobutiophenone (a-PBP) ......................................................................................................................................
alpha-Pyrrolidinopentiophenone (a-PVP) ....................................................................................................................................
Aminorex ......................................................................................................................................................................................
Benzylmorphine ...........................................................................................................................................................................
Betacetylmethadol .......................................................................................................................................................................
beta-Hydroxy-3-methylfentanyl ....................................................................................................................................................
beta-Hydroxyfentanyl ...................................................................................................................................................................
Betameprodine .............................................................................................................................................................................
Betamethadol ...............................................................................................................................................................................
Betaprodine ..................................................................................................................................................................................
Bufotenine ....................................................................................................................................................................................
Cathinone .....................................................................................................................................................................................
Codeine methylbromide ...............................................................................................................................................................
Codeine-N-oxide ..........................................................................................................................................................................
Desomorphine ..............................................................................................................................................................................
Diethyltryptamine .........................................................................................................................................................................
Difenoxin ......................................................................................................................................................................................
Dihydromorphine ..........................................................................................................................................................................
Dimethyltryptamine ......................................................................................................................................................................
Dipipanone ...................................................................................................................................................................................
Fenethylline ..................................................................................................................................................................................
gamma-Hydroxybutyric acid ........................................................................................................................................................
Heroin ..........................................................................................................................................................................................
Hydromorphinol ............................................................................................................................................................................
Hydroxypethidine .........................................................................................................................................................................
Ibogaine .......................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ................................................................................................................................................
Marihuana ....................................................................................................................................................................................
Mescaline .....................................................................................................................................................................................
Methaqualone ..............................................................................................................................................................................
Methcathinone .............................................................................................................................................................................
Methyldesorphine .........................................................................................................................................................................
VerDate Mar<15>2010
15:14 Sep 05, 2014
Jkt 232001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
E:\FR\FM\08SEN1.SGM
08SEN1
15
15
25
25
25
30
30
25
55
50
40
50
35
15
2
2
25
25
15
100
25
25
15
45
15
68
53
25
25
25
2
2
2
2
2
25
2
2
2
2
25
15
15
25
2
2
2
2
2
4
2
3
70
5
305
5
25
50
3,990,000
35
5
5
70,250,000
25
2
2
5
35
125,000
25
10
25
5
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices
53219
Established
2015 quotas (g)
Basic class
Methyldihydromorphine ................................................................................................................................................................
Morphine methylbromide .............................................................................................................................................................
Morphine methylsulfonate ............................................................................................................................................................
Morphine-N-oxide ........................................................................................................................................................................
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ................................................................................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA) .............................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) ..................................
N,N-Dimethylamphetamine ..........................................................................................................................................................
Naphthylpyrovalerone (naphyrone) .............................................................................................................................................
N-Benzylpiperazine ......................................................................................................................................................................
N-Ethyl-1-phenylcyclohexylamine ................................................................................................................................................
N-Ethylamphetamine ...................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ..............................................................................................................................
Noracymethadol ...........................................................................................................................................................................
Norlevorphanol .............................................................................................................................................................................
Normethadone .............................................................................................................................................................................
Normorphine ................................................................................................................................................................................
Phenomorphan ............................................................................................................................................................................
Psilocybin .....................................................................................................................................................................................
Psilocyn ........................................................................................................................................................................................
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) ................................................................
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22; QUPIC) ................................................................................................
Tetrahydrocannabinols ................................................................................................................................................................
Thiofentanyl .................................................................................................................................................................................
Tilidine ..........................................................................................................................................................................................
Trimeperidine ...............................................................................................................................................................................
2
5
5
350
15
15
15
25
15
25
5
24
24
2
52
2
18
2
30
30
15
15
497,500
2
10
2
Schedule II
rmajette on DSK2TPTVN1PROD with NOTICES
1-Phenylcyclohexylamine ............................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile ............................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) .................................................................................................................................
Alfentanil ......................................................................................................................................................................................
Alphaprodine ................................................................................................................................................................................
Amobarbital ..................................................................................................................................................................................
Amphetamine (for conversion) ....................................................................................................................................................
Amphetamine (for sale) ...............................................................................................................................................................
Carfentanil ....................................................................................................................................................................................
Cocaine ........................................................................................................................................................................................
Codeine (for conversion) .............................................................................................................................................................
Codeine (for sale) ........................................................................................................................................................................
Dextropropoxyphene ....................................................................................................................................................................
Dihydrocodeine ............................................................................................................................................................................
Diphenoxylate ..............................................................................................................................................................................
Ecgonine ......................................................................................................................................................................................
Ethylmorphine ..............................................................................................................................................................................
Fentanyl .......................................................................................................................................................................................
Glutethimide .................................................................................................................................................................................
Hydrocodone (for conversion) .....................................................................................................................................................
Hydrocodone (for sale) ................................................................................................................................................................
Hydromorphone ...........................................................................................................................................................................
Isomethadone ..............................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ................................................................................................................................................
Levomethorphan ..........................................................................................................................................................................
Levorphanol .................................................................................................................................................................................
Lisdexamfetamine ........................................................................................................................................................................
Meperidine ...................................................................................................................................................................................
Meperidine Intermediate-A ..........................................................................................................................................................
Meperidine Intermediate-B ..........................................................................................................................................................
Meperidine Intermediate-C ..........................................................................................................................................................
Metazocine ...................................................................................................................................................................................
Methadone (for sale) ...................................................................................................................................................................
Methadone Intermediate ..............................................................................................................................................................
Methamphetamine .......................................................................................................................................................................
5
5
2,687,500
17,750
3
25,125
21,875,000
37,500,000
19
275,000
50,000,000
49,500,000
19
226,375
1,337,500
174,375
3
2,150,000
3
137,500
99,625,000
7,000,000
5
4
5
7,125
29,750,000
6,250,000
6
11
6
19
31,875,000
34,375,000
2,061,375
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly
for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)]
Methylphenidate ...........................................................................................................................................................................
Morphine (for conversion) ............................................................................................................................................................
Morphine (for sale) ......................................................................................................................................................................
Nabilone .......................................................................................................................................................................................
Noroxymorphone (for conversion) ...............................................................................................................................................
VerDate Mar<15>2010
15:14 Sep 05, 2014
Jkt 232001
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
E:\FR\FM\08SEN1.SGM
08SEN1
83,750,000
91,250,000
62,500,000
18,750
17,500,000
53220
Federal Register / Vol. 79, No. 173 / Monday, September 8, 2014 / Notices
Established
2015 quotas (g)
Basic class
Noroxymorphone (for sale) ..........................................................................................................................................................
Opium (powder) ...........................................................................................................................................................................
Opium (tincture) ...........................................................................................................................................................................
Oripavine ......................................................................................................................................................................................
Oxycodone (for conversion) ........................................................................................................................................................
Oxycodone (for sale) ...................................................................................................................................................................
Oxymorphone (for conversion) ....................................................................................................................................................
Oxymorphone (for sale) ...............................................................................................................................................................
Pentobarbital ................................................................................................................................................................................
Phenazocine ................................................................................................................................................................................
Phencyclidine ...............................................................................................................................................................................
Phenmetrazine .............................................................................................................................................................................
Phenylacetone .............................................................................................................................................................................
Racemethorphan .........................................................................................................................................................................
Remifentanil .................................................................................................................................................................................
Secobarbital .................................................................................................................................................................................
Sufentanil .....................................................................................................................................................................................
Tapentadol ...................................................................................................................................................................................
Thebaine ......................................................................................................................................................................................
1,475,000
112,500
687,500
35,000,000
8,350,000
137,500,000
29,000,000
7,750,000
35,000,000
6
19
3
9,375,000
3
3,750
215,003
6,255
12,500,000
125,000,000
List I Chemicals
Ephedrine (for conversion) ..........................................................................................................................................................
Ephedrine (for sale) .....................................................................................................................................................................
Phenylpropanolamine (for conversion) ........................................................................................................................................
Phenylpropanolamine (for sale) ...................................................................................................................................................
Pseudoephedrine (for conversion) ..............................................................................................................................................
Pseudoephedrine (for sale) .........................................................................................................................................................
The Deputy Administrator also
establishes aggregate production quotas
for all other schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 at zero. In accordance with
21 CFR 1303.13 and 21 CFR 1315.13,
upon consideration of the relevant
factors, the Deputy Administrator may
adjust the 2015 aggregate production
quotas and assessment of annual needs
as needed.
Dated: September 2, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014–21280 Filed 9–5–14; 8:45 am]
BILLING CODE 4410–09–P
OFFICE OF SCIENCE AND
TECHNOLOGY POLICY
National Nanotechnology Coordination
Office
Nanoscale Science, Engineering, and
Technology Subcommittee; Committee
on Technology, National Science and
Technology Council; Meeting
rmajette on DSK2TPTVN1PROD with NOTICES
ACTION:
Notice of public meeting.
The National Nanotechnology
Coordination Office (NNCO), on behalf
of the Nanoscale Science, Engineering,
and Technology (NSET) Subcommittee
of the Committee on Technology,
National Science and Technology
Council (NSTC), will hold a technical
SUMMARY:
VerDate Mar<15>2010
15:14 Sep 05, 2014
Jkt 232001
interchange meeting entitled ‘‘Realizing
the Promise of Carbon Nanotubes—
Challenges, Opportunities and the
Pathway to Commercialization’’ on
September 15, 2014. The meeting will
be sponsored by the National
Nanotechnology Initiative (NNI) and cosponsored by the National Aeronautics
and Space Administration (NASA). The
objectives of this meeting are to identify,
discuss, and report the technical
barriers preventing the production of
carbon nanotube-based materials with
electrical and mechanical properties
approaching theoretical values, and to
explore ways to overcome these barriers.
Obstacles preventing the full
exploitation of the multifunctional
nature of carbon nanotube materials will
also be discussed. This one-day meeting
will assemble some of the Nation’s
leading experts in carbon nanotube
research and development, as well as
executives and experts from the Federal
government, academia, and private
sector.
The technical interchange
meeting will be held Monday,
September 15, 2014 from 8:00 a.m. until
5:15 p.m.
ADDRESSES: The technical interchange
meeting will be held at the National
Aeronautics and Space Administration
(NASA) Headquarters, 300 E Street
Southwest, Washington, DC 20546.
FOR FURTHER INFORMATION, CONTACT: Dr.
Tarek Fadel, 703–292–7926, tfadel@
DATES:
PO 00000
Frm 00059
Fmt 4703
Sfmt 9990
1,000,000
4,000,000
44,800,000
8,500,000
7,000
224,500,000
nnco.nano.gov, NNCO. Additional
information is posted at: https://
nano.gov/2014CNTTechInterchange.
Registration: Registration opens on
September 8, 2014. Due to space
limitations, pre-registration for the
technical interchange meeting is
required. Written notices of
participation by email should be sent to
dpetreski@nnco.nano.gov or mailed to
Diana Petreski, 4201 Wilson Blvd.,
Stafford II, Suite 405, Arlington, VA
22230. Please provide your full name,
title, affiliation and email or mailing
address when registering. Registration is
on a first-come, first-served basis until
capacity is reached. Written or
electronic comments should be
submitted by email to dpetreski@
nnco.nano.gov until close of business
September 10, 2014.
Meeting Accommodations:
Individuals requiring special
accommodation to access this meeting
should contact Diana Petreski at 703–
292–7922 at least five business days
prior to the meeting so that appropriate
arrangements can be made.
Ted Wackler,
Deputy Chief of Staff and Assistant Director.
[FR Doc. 2014–21201 Filed 9–5–14; 8:45 am]
BILLING CODE P
E:\FR\FM\08SEN1.SGM
08SEN1
Agencies
[Federal Register Volume 79, Number 173 (Monday, September 8, 2014)]
[Notices]
[Pages 53216-53220]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-21280]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-393]
Established Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2015
AGENCY: Drug Enforcement Administration (DEA), Department of Justice
(DOJ).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice establishes the initial 2015 aggregate production
quotas for controlled substances in schedules I and II of the
Controlled Substances Act (CSA) and the assessment of annual needs for
the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine.
DATES: Effective date: Effective September 8, 2014.
FOR FURTHER INFORMATION CONTACT: Imelda Paredes, Executive Assistant,
Office of Diversion Control, Drug Enforcement Administration, 8701
Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598-6812.
SUPPLEMENTARY INFORMATION:
Legal Authority
The Drug Enforcement Administration (DEA) implements and enforces
titles II and III of the Comprehensive Drug Abuse Prevention and
Control Act of 1970, as amended. Titles II and III are referred to as
the ``Controlled Substances Act'' and the ``Controlled Substances
Import and Export Act,'' respectively, and are collectively referred to
as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of
this action. 21 U.S.C. 801-971. The DEA publishes the implementing
regulations for these statutes in title 21 of the Code of Federal
Regulations (CFR), parts 1300 to 1321. The CSA and its implementing
regulations are designed to prevent, detect, and eliminate the
diversion of controlled substances and listed chemicals into the
illicit market while providing for the legitimate medical, scientific,
research, and industrial needs of the United States. Controlled
substances have the potential for abuse and dependence and are
controlled to protect the public health and safety.
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826)
requires the Attorney General to establish aggregate production quotas
for each basic class of controlled substance listed in schedules I and
II and for ephedrine, pseudoephedrine, and phenylpropanolamine. This
responsibility has been delegated to the Administrator of the DEA
through 28 CFR 0.100(b). The Administrator, in turn, has redelegated
this function to the Deputy Administrator, pursuant to 28 CFR pt. 0
subpt. R, App.
Background
The 2015 aggregate production quotas and assessment of annual needs
represent those quantities of schedule I and II controlled substances
and the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine to be manufactured in the United States in 2015 to
provide for the estimated medical, scientific, research, and industrial
needs of the United States, lawful export requirements, and the
establishment and maintenance of reserve stocks. These quotas include
imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do
not include imports of controlled substances for use in industrial
processes.
On July 2, 2014, a notice titled, ``Proposed Aggregate Production
Quotas for Schedule I and II Controlled Substances and Proposed
Assessment of Annual Needs for the List I Chemicals Ephedrine,
Pseudoephedrine, and Phenylpropanolamine for 2015'' was published in
the Federal Register. 79 FR 37772. This notice proposed the 2015
aggregate production quotas for each basic class of controlled
substance listed in schedules I and II and the 2015 assessment of
annual needs for the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. All interested persons were invited to comment on
or object to the proposed aggregate production quotas and the proposed
assessment of annual needs on or before August 1, 2014.
Comments Received
Five comments were received from DEA-registered manufacturers
within the published comment period, offering comments on a total of 32
schedule I and II controlled substances. None of the respondents
commented on the list I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine. Commenters stated that the proposed aggregate
production quotas for 1-(1,3-Benzodioxol-5-yl)-2-(methylamino) butan-1-
one (butylone), 1-(1,3-Benzodioxol-5-yl)-2-(methylamino) pentan-1-one
(pentylone), 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe), 2-(4-Chloro-2,5-dimethoxyphenyl)-
N-(2-methoxybenzyl)ethanamine (25C-NBOMe), 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), 2-
(Methylamino)-1-phenylpentan-1-one (pentedrone), 3-Fluoro-N-
methylcathinone (3-FMC), 4-Fluoro-N-methylcathinone (4-FMC), 4-Anilino-
N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4-MEC), 4-
Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP), alpha-
Pyrrolidinobutiophenone ([alpha]-PBP), alpha-Pyrrolidinopentiophenone
([alpha]-PVP), amphetamine (for sale), codeine (for sale),
dihydrocodeine, diphenoxylate, fentanyl, hydrocodone (for sale),
hydromorphone, levorphanol, marihuana, morphine (for conversion), N-(1-
Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
(ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide (AB-FUBINACA), naphthylpyrovalerone
(naphyrone), oripavine, oxycodone (for conversion), oxymorphone (for
conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-
1H-indole-3-carboxylate (PB-22) were insufficient to provide for the
estimated medical, scientific, research, and industrial needs of the
United States, export requirements, and the establishment and
maintenance of reserve stocks.
Determination of 2015 Aggregate Production Quotas and Assessment of
Annual Needs
In determining the 2015 aggregate production quotas and assessment
of annual needs, the DEA has taken into consideration the above
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR
1315.11, in accordance with 21 U.S.C. 826 (a), and other relevant
factors, including the consideration of 2014 manufacturing quotas,
current 2014 sales and inventories, 2015 export requirements,
industrial use, additional applications for quotas, as well as
information on research and product development requirements. Based on
this information, the DEA has determined
[[Page 53217]]
that adjustments to the proposed aggregate production quotas and
assessment of annual needs for alfentanil, cocaine, codeine-N-oxide,
codeine (for sale), dihydrocodeine, fentanyl, hydromorphone,
levorphanol, marihuana, oripavine, oxymorphone (for conversion), and
ephedrine (for sale) are warranted. This notice reflects those
adjustments.
Regarding 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one
(butylone), 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one
(pentylone), 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe), 2-(4-Chloro-2,5-dimethoxyphenyl)-
N-(2-methoxybenzyl)ethanamine (25C-NBOMe), 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), 2-
(Methylamino)-1-phenylpentan-1-one (pentedrone), 3-Fluoro-N-
methylcathinone (3-FMC), 4-Fluoro-N-methylcathinone (4-FMC), 4-Anilino-
N-phenethyl-4-piperidine (ANPP), 4-Methyl-N-ethylcathinone (4-MEC), 4-
Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP), alpha-
Pyrrolidinobutiophenone ([alpha]-PBP), alpha-Pyrrolidinopentiophenone
([alpha]-PVP), amphetamine (for sale), dihydrocodeine, fentanyl,
hydromorphone, levorphanol, marihuana, N-(1-Amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB-PINACA), N-(1-
Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
carboxamide (AB-FUBINACA), naphthylpyrovalerone (naphyrone), oxycodone
(for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-
fluoropentyl)-1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-
yl 1-pentyl-1H-indole-3-carboxylate (PB-22), the DEA has determined
that the proposed aggregate production quotas are sufficient to provide
for the 2015 estimated medical, scientific, research, and industrial
needs of the United States, export requirements, and the establishment
and maintenance of reserve stocks. This notice finalizes these
aggregate production quotas at the same amounts as proposed.
As described in the previously published notice proposing the 2015
aggregate production quotas and assessment of annual needs, the DEA has
specifically considered that inventory allowances granted to individual
manufacturers may not always result in the availability of sufficient
quantities to maintain an adequate reserve stock pursuant to 21 U.S.C.
826(a), as intended. See 21 CFR 1303.24. This would be concerning if a
natural disaster or other unforeseen event resulted in substantial
disruption to the amount of controlled substances available to provide
for legitimate public need. As such, the DEA has included in all
established schedule II aggregate production quotas, and certain
schedule I aggregate production quotas, an additional 25% of the
estimated medical, scientific, and research needs as part of the amount
necessary to ensure the establishment and maintenance of reserve
stocks. The resulting established aggregate production quota will
reflect these included amounts. This action will not affect the ability
of manufacturers to maintain inventory allowances as specified by
regulation. The DEA expects that maintaining this reserve in certain
established aggregate production quotas will mitigate adverse public
effects if an unforeseen event results in the substantial disruption to
the amount of controlled substances available to provide for legitimate
public need, as determined by the DEA. The DEA does not anticipate
utilizing the reserve in the absence of these circumstances.
In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR
1315.11, the Deputy Administrator hereby establishes the 2015 aggregate
production quotas for the following schedule I and II controlled
substances and the 2015 assessment of annual needs for the list I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine,
expressed in grams of anhydrous acid or base, as follows:
------------------------------------------------------------------------
Established 2015
Basic class quotas (g)
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 15
tetramethylcyclopropyl)methanone (UR-144)..........
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 15
tetramethylcyclopropyl)methanone (XLR11)...........
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one 15
(butylone).........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one 15
(pentylone)........................................
1-(1-Phenylcyclohexyl)pyrrolidine................... 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)... 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).. 45
1-[1-(2-Thienyl)cyclohexyl]piperidine............... 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole 45
(JWH-200)..........................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)............. 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole 45
(SR-18 and RCS-8)..................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)............. 45
1-Methyl-4-phenyl-4-propionoxypiperidine............ 2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678).. 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)... 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250).. 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)... 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)... 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS- 45
4).................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081). 45
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P). 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).... 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)... 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)... 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)............ 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
25B; Cimbi-36).....................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)... 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
25C; Cimbi-82).....................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)..... 30
[[Page 53218]]
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2- 15
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
25I; Cimbi-5)......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone)... 15
2,5-Dimethoxy-4-ethylamphetamine (DOET)............. 25
2,5-Dimethoxy-4-n-propylthiophenethylamine.......... 25
2,5-Dimethoxyamphetamine............................ 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C- 30
T-2)...............................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 30
(2C-T-4)...........................................
3,4,5-Trimethoxyamphetamine......................... 25
3,4-Methylenedioxyamphetamine (MDA)................. 55
3,4-Methylenedioxymethamphetamine (MDMA)............ 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)........ 40
3,4-Methylenedioxy-N-methylcathinone (methylone).... 50
3,4-Methylenedioxypyrovalerone (MDPV)............... 35
3-Fluoro-N-methylcathinone (3-FMC).................. 15
3-Methylfentanyl.................................... 2
3-Methylthiofentanyl................................ 2
4-Bromo-2,5-dimethoxyamphetamine (DOB).............. 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB).......... 25
4-Fluoro-N-methylcathinone (4-FMC).................. 15
4-Methoxyamphetamine................................ 100
4-Methyl-2,5-dimethoxyamphetamine (DOM)............. 25
4-Methylaminorex.................................... 25
4-Methyl-N-ethylcathinone (4-MEC)................... 15
4-Methyl-N-methylcathinone (mephedrone)............. 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP). 15
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- 68
hydroxycyclohexyl]-phenol..........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3- 53
hydroxycyclohexyl]-phenol (cannabicyclohexanol or
CP-47,497 C8-homolog)..............................
5-Methoxy-3,4-methylenedioxyamphetamine............. 25
5-Methoxy-N,N-diisopropyltryptamine................. 25
5-Methoxy-N,N-dimethyltryptamine.................... 25
Acetyl-alpha-methylfentanyl......................... 2
Acetyldihydrocodeine................................ 2
Acetylmethadol...................................... 2
Allylprodine........................................ 2
Alphacetylmethadol.................................. 2
alpha-Ethyltryptamine............................... 25
Alphameprodine...................................... 2
Alphamethadol....................................... 2
alpha-Methylfentanyl................................ 2
alpha-Methylthiofentanyl............................ 2
alpha-Methyltryptamine (AMT)........................ 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)......... 15
alpha-Pyrrolidinopentiophenone ([alpha]-PVP)........ 15
Aminorex............................................ 25
Benzylmorphine...................................... 2
Betacetylmethadol................................... 2
beta-Hydroxy-3-methylfentanyl....................... 2
beta-Hydroxyfentanyl................................ 2
Betameprodine....................................... 2
Betamethadol........................................ 4
Betaprodine......................................... 2
Bufotenine.......................................... 3
Cathinone........................................... 70
Codeine methylbromide............................... 5
Codeine-N-oxide..................................... 305
Desomorphine........................................ 5
Diethyltryptamine................................... 25
Difenoxin........................................... 50
Dihydromorphine..................................... 3,990,000
Dimethyltryptamine.................................. 35
Dipipanone.......................................... 5
Fenethylline........................................ 5
gamma-Hydroxybutyric acid........................... 70,250,000
Heroin.............................................. 25
Hydromorphinol...................................... 2
Hydroxypethidine.................................... 2
Ibogaine............................................ 5
Lysergic acid diethylamide (LSD).................... 35
Marihuana........................................... 125,000
Mescaline........................................... 25
Methaqualone........................................ 10
Methcathinone....................................... 25
Methyldesorphine.................................... 5
[[Page 53219]]
Methyldihydromorphine............................... 2
Morphine methylbromide.............................. 5
Morphine methylsulfonate............................ 5
Morphine-N-oxide.................................... 350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide 15
(AKB48)............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H- 15
indazole-3-carboxamide (ADB-PINACA)................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4- 15
fluorobenzyl)-1H-indazole-3-carboxamide (AB-
FUBINACA)..........................................
N,N-Dimethylamphetamine............................. 25
Naphthylpyrovalerone (naphyrone).................... 15
N-Benzylpiperazine.................................. 25
N-Ethyl-1-phenylcyclohexylamine..................... 5
N-Ethylamphetamine.................................. 24
N-Hydroxy-3,4-methylenedioxyamphetamine............. 24
Noracymethadol...................................... 2
Norlevorphanol...................................... 52
Normethadone........................................ 2
Normorphine......................................... 18
Phenomorphan........................................ 2
Psilocybin.......................................... 30
Psilocyn............................................ 30
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3- 15
carboxylate (5-fluoro-PB-22; 5F-PB-22).............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB- 15
22; QUPIC).........................................
Tetrahydrocannabinols............................... 497,500
Thiofentanyl........................................ 2
Tilidine............................................ 10
Trimeperidine....................................... 2
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine............................. 5
1-Piperidinocyclohexanecarbonitrile................. 5
4-Anilino-N-phenethyl-4-piperidine (ANPP)........... 2,687,500
Alfentanil.......................................... 17,750
Alphaprodine........................................ 3
Amobarbital......................................... 25,125
Amphetamine (for conversion)........................ 21,875,000
Amphetamine (for sale).............................. 37,500,000
Carfentanil......................................... 19
Cocaine............................................. 275,000
Codeine (for conversion)............................ 50,000,000
Codeine (for sale).................................. 49,500,000
Dextropropoxyphene.................................. 19
Dihydrocodeine...................................... 226,375
Diphenoxylate....................................... 1,337,500
Ecgonine............................................ 174,375
Ethylmorphine....................................... 3
Fentanyl............................................ 2,150,000
Glutethimide........................................ 3
Hydrocodone (for conversion)........................ 137,500
Hydrocodone (for sale).............................. 99,625,000
Hydromorphone....................................... 7,000,000
Isomethadone........................................ 5
Levo-alphacetylmethadol (LAAM)...................... 4
Levomethorphan...................................... 5
Levorphanol......................................... 7,125
Lisdexamfetamine.................................... 29,750,000
Meperidine.......................................... 6,250,000
Meperidine Intermediate-A........................... 6
Meperidine Intermediate-B........................... 11
Meperidine Intermediate-C........................... 6
Metazocine.......................................... 19
Methadone (for sale)................................ 31,875,000
Methadone Intermediate.............................. 34,375,000
Methamphetamine..................................... 2,061,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
non-prescription product; 750,000 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,375 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate..................................... 83,750,000
Morphine (for conversion)........................... 91,250,000
Morphine (for sale)................................. 62,500,000
Nabilone............................................ 18,750
Noroxymorphone (for conversion)..................... 17,500,000
[[Page 53220]]
Noroxymorphone (for sale)........................... 1,475,000
Opium (powder)...................................... 112,500
Opium (tincture).................................... 687,500
Oripavine........................................... 35,000,000
Oxycodone (for conversion).......................... 8,350,000
Oxycodone (for sale)................................ 137,500,000
Oxymorphone (for conversion)........................ 29,000,000
Oxymorphone (for sale).............................. 7,750,000
Pentobarbital....................................... 35,000,000
Phenazocine......................................... 6
Phencyclidine....................................... 19
Phenmetrazine....................................... 3
Phenylacetone....................................... 9,375,000
Racemethorphan...................................... 3
Remifentanil........................................ 3,750
Secobarbital........................................ 215,003
Sufentanil.......................................... 6,255
Tapentadol.......................................... 12,500,000
Thebaine............................................ 125,000,000
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion).......................... 1,000,000
Ephedrine (for sale)................................ 4,000,000
Phenylpropanolamine (for conversion)................ 44,800,000
Phenylpropanolamine (for sale)...................... 8,500,000
Pseudoephedrine (for conversion).................... 7,000
Pseudoephedrine (for sale).......................... 224,500,000
------------------------------------------------------------------------
The Deputy Administrator also establishes aggregate production
quotas for all other schedule I and II controlled substances included
in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR
1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors,
the Deputy Administrator may adjust the 2015 aggregate production
quotas and assessment of annual needs as needed.
Dated: September 2, 2014.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2014-21280 Filed 9-5-14; 8:45 am]
BILLING CODE 4410-09-P